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Background: Discrepant thyroid function tests (TFTs) are typical of inappropriate
secretion of TSH (IST), a rare entity encompassing TSH-secreting adenomas (TSHoma)
and Resistance to Thyroid Hormone (RTHβ) due to THRB mutations. The differential
diagnosis remains a clinical challenge in most of the cases. The objective of this study
was to share our experience with patients presenting with discrepant TFTs outlining the
main pitfalls in the differential diagnosis.
Methods: medical records of 100 subjects with discrepant TFTs referred to
Thyroid Endocrine Centers at the University of Milan were analyzed, retrospectively.
Patients were studied by dynamic testing (TRH test, T3-suppression test, or a short
course of long-acting somatostatin analog, when appropriate), THRB sequencing, and
pituitary imaging.
Results: 88 patients were correctly diagnosed as RTHβ with (n = 59; 16 men, 43
women) or without THRB variants (n = 6; 2 men, 4 female) or TSHoma (n = 23; 9
men, 14 women). We identified 14 representative subjects with an atypical presentation
or who were misdiagnosed. Seven patients, with spurious hyperthyroxinemia due to
assays interference were erroneously classified as RTHβ (n = 4) or TSHoma (n = 3).
Three patients with genuine TSHomas were classified as laboratory artifact (n = 2) or
RTHβ (n = 1). Two TSHomas presented atypically due to coexistent primary thyroid
diseases. In one RTHβ a drug-induced thyroid dysfunction was primarily assumed.
Campi et al. Differential Diagnosis of Central Hyperthyroidism
These patients experienced a mean diagnostic delay of 26 ± 14 months. Analysis of
the investigations which can differentiate between TSHoma and RTHβ showed highest
accuracy for the T3-suppression test (100% specificity with a cut-off of TSH <0.11
µUI/ml). Pituitary MRI was negative in 6/26 TSHomas, while 11/45 RTHβ patients had
small pituitary lesions, leading to unnecessary surgery in one case.
Conclusions: Diagnostic delay and inappropriate treatments still occur in too many
cases with discrepant TFTs suggestive of central hyperthyroidism. The insistent pitfalls
lead to a significant waste of resources. We propose a revised flow-chart for the
differential diagnosis.
Keywords: hyperthyroidism, pituitary adenoma, resistance to thyroid hormone, thyroid hormone, thyrotropin
(TSH), immuno-assay
INTRODUCTION
TSH secreting pituitary adenomas (TSHomas) and Resistance to
Thyroid Hormone due to mutations in the THRB gene (RTHβ)
are two possible underlying causes of the rare clinical entity of
inappropriate secretion of TSH (IST), which is characterized by
hyperthyroxinemia and non-suppressed TSH levels.
The differential diagnosis of IST is often challenging (1).
Major factors hampering diagnosis are the low incidence of the
condition, insufficient awareness or experience of diagnosis and
management, and absence of diagnostic tests with high sensitivity
or specificity (2–4).
Laboratory artifacts resulting in discrepant thyroid function
tests (TFTs)may arise due to anti-T4 or heterophile antibodies (5)
or abnormal concentration or affinity of TH transport proteins
(TBG, albumin, and transthyretin) (6); these conditions are
significantly more frequent than genuine IST, and as such, result
in real potential for misdiagnosis (7). The coexistence of a
primary thyroid disorder is frequent, particularly in areas of
mild/moderate iodine deficiency (8) and might cause additional
diagnostic uncertainty (9, 10). Finally, once a diagnosis of IST is
confirmed, TSHomas must be differentiated from RTHβ, due to
different management and therapy of these disorders (1).
Several tests and strategies for the differential diagnosis
of TSHomas have been proposed, and include biochemical
parameters (e.g., SHBG, markers of bone metabolism, serum
alpha subunit) (11–13), dynamic testing (e.g., TRH stimulation
or T3 suppression tests) (14–19) or a short course of long-acting
somatostatin analog (LAR–SMS) administration (20), in addition
to pituitary MRI scan and THRB sequencing (1). However,
several of these investigations are not sufficiently discriminatory,
or are available only in some centers; in addition they may
be contra-indicated in some cases, or be overly cumbersome
and expensive to perform. Thus the differential diagnosis of
discrepant TFTs remains a clinical challenge.
Our study aims to share our experience of patients presenting
with discrepant TFTs outlining themain pitfalls in the differential
diagnosis of IST. In particular, we highlight 14 particular
cases with either an atypical clinical presentation or which
exemplify consequences of misdiagnosis. Our study shows that
an excessive number of patients still experience delayed diagnosis
or inappropriate and harmful treatment, with attendant waste of
resources and care costs.
MATERIALS AND METHODS
Study Protocol
Medical records of 121 subjects, referred to Endocrine Centers at
the University ofMilan, in the period 1997–2018 for investigation
of IST were analyzed, retrospectively.
We considered as the gold standard for diagnosis of RTHβ the
identification of THRB mutation located in the three hotspots
of the ligand binding domain of the receptor. The absence of
a THRB mutation despite a clear RTHβ phenotype led to a
classification of non-TH RTHβ (21).
The diagnosis of a TSHoma depended upon the combination
of several findings, because the frequency of incidental pituitary
lesions rendered often inadequate the association of IST and a
positive pituitary imaging. Confirmations of a TSHoma were the
remission of biochemical alterations and clinical manifestations
after pituitary surgery or radiotherapy, or during medical
treatment with somatostatin analogs. This latter condition was
also accepted as a proof of TSHoma as TFTs can be only
transiently affected by the acute administration of somatostatin
in RTHβ, but no normalization or even decreases of circulating
free thyroid hormones can be seen in RTHβ patients on chronic
somatostatin analogs (1, 20).
We excluded from the analysis of dynamic testing RTHβ
patients previously submitted to thyroidectomy or 131-I
radiometabolic therapy (n = 4). We also excluded patients with
RTHβ without mutations in the THRB gene (non-TR-RTHβ)
(21) who were lost to follow-up (n = 17), although their initial
investigations were consistent with RTH and not significantly
different compared with patients harboring dominant negative
variants in the THRB gene (Figure 1).
RTHβwas ultimately diagnosed in sixty-one patients (16 men,
45 women), a non-TR-RTHβ in six, and a TSHoma in 26 cases
(9 men, 17 women; 8 macroadenomas, and 18 microadenomas).
The remaining seven patients had spurious hyperthyroxinaemia
due to interference in thyroid hormone measurement (Figure 1).
The 6 patients with non-TR-RTHβ (21) were tested by TRH
test, T3 suppression test, and pituitary MRI at diagnosis and
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FIGURE 1 | Selection process of the medical record included in this survey. Of the 121 files screened, 100 cases were included in the final analysis. See also Table 2
for further details.
two or three times during follow-up (range 7–12 years). Because
these patients have a different and unknown molecular cause of
peripheral resistance, their response to dynamic testing was not
considered for the definition of the proposed cut-offs.
Imaging data and dynamic testing of patients with genuine
RTHβ due toTHRB genemutations and TSHomawere compared
to a control group of 105 controls (36 males, 69 females).
The controls were recruited in different ways: (a) volunteers
among the personnel of the involved clinical and laboratory
units; (b) subjects demonstrated to have normal thyroid function
tests after retesting at our Laboratory; (c) patients presenting
with unconfirmed hyperprolactinemia; (d) incidental pituitary
microlesions <5mm that were not confirmed at targeted
radiological examinations or were found to be non-functional
at biochemical testing and upon follow-up of at least 7 years.
These subjects gave informed consent for testing and publication
of anonymized data for research purposes.
A portion of controls had euthyroid autoimmune thyroid
disease (AITD) (33%). These were included in the control group
in order to obtain a correct matching since 20 and 32% of RTHβ
and TSHoma, respectively, had an associated AITD (Table 1).
None of the patients was taking anti-thyroid drugs.
From these records, we have highlighted 14 representative
cases either with an atypical clinical presentation or
misdiagnosed. Eleven patients were females and three were
males; their mean age ± SD was 39 ± 16 years (range 19–72
years), with a mean ± SD duration of clinical assessments of 26
± 14 months (range 6–60).
Dynamic Tests
Dynamic tests were performed as previously reported (14–20).
TRH test was performed by administering 200 µg of TRH
intravenously and assessing TSH at baseline, 20, 30, and 60min
after TRH injection. TSH response was defined as the highest
TSH peak after TRH (which occurred in all subjects between 20
and 30min after TRH). The TSH fold increase was calculated
as the ratio between the TSH peak and baseline TSH (14). This
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TABLE 1 | Clinical characteristics of patients and controls included in the study.
Controls TSHomas RTHβ P
N 105 26 61
Males/females (n) 36/69 9/17 16/45 NS
AITD (n) 31 5 21 NS
Age (years) 39 ± 15 42 ± 13 34 ± 15 <0.05*; NS#§
Baseline TSH
(µUI/ml)
2.3 ± 1.6 3.5 ± 2.6 2.4 ± 2.0 NS*; <0.05#§
Baseline FT4
(pmol/l)
12.6 ± 2.8 28.1 ± 6.7 32.2 ± 12.2 <0.05*#; NS§
Baseline FT3
(pmol/l)
5.4 ± 1.2 11.1 ± 3.8 10.1 ± 4.3 <0.05*#; NS§
Expansive lesions
at pituitary MRI
4/25 20/26 11/45 <0.001#§;
NS*
TRH test (n) 103 24 61
TSH peak (µUI/ml) 16.7 ± 12.4 7.7 ± 7.2 19.0 ± 13.1 <0.001#§;
NS*
TSH fold increase 7.8 ± 3.3 2.3 ± 1.6 9.3 ± 4.9 <0.001#§*
delta increase TSH
(µUI/ml)
14.4 ± 11.2 3.9 ± 5.6 16.5 ± 11.5 <0.001#§;
NS*
T3 suppression (n) 15 19 16
TSH (µUI/ml) at
day 10
0.02 ± 0.02 1.9 ± 1.5 0.3 ± 0.5 <0.0001#§;
NS*
Data are expressed as mean ± SD; abnormal values are indicated in bold.
*Between RTHβ and controls; §between RTHβ and TSHoma; #between TSHoma
and controls. IST, inappropriate secretion of TSH; FDH, Familial Dysalbuminemic
Hypothyroxinemia; MRI, magnetic resonance imaging; AITD, autoimmune thyroid
disorders. Test: one way ANOVA, chi-square test.
Reference ranges: TSH 0.3–5.1 mU/L; FT4 10–20 pmol/L; FT3 4.2–7.5 pmol/L.
test was performed in 98, 100, and 90% of controls, RTHβ, and
TSHoma, respectively.
T3 suppression test was performed administering fixed doses
of 100 µg of sodium liothyronine divided in three doses of 40 +
20 + 40 µg (every 8 h) given by mouth for 10 days (18). TSH
was measured at baseline and 2 h after the last dose of T3. Sixty
mg/day of propranolol were given in case of heart rate >110
beats/min. The T3 suppression test was performed in 14, 26, and
70% of controls, RTHβ, and TSHoma, respectively. In most of
these cases the TRH test, as described above, was repeated after
T3 suppression and TRH was injected 2 h after the last T3 dose.
For the LAR-SMS test 30mg of the somatostatin analog was
administered every 28 days for 2–3 months in 13 TSHoma and 4
RTHβ. TSH FT4 and FT3 were measured at baseline, before each
injection and 28 days after the last one (20).
Thyroid function was assayed on the two-step immunoassay
DELFIA platform (PerkinElmer Turku, Finland) in the majority
of the cases and on Elecsys 2010 and Cobas 6000 analyzer (Roche,
Basil, Switzerland) in the remaining 20% of cases. Since during
the study period both these assays underwent upgrading of the
methods by the manufacturer, the cross comparison of FT4 and
FT3 (expressed in pmol/L) levels was undertaken after expressing
them as a percentage of the upper limit of the assay normal range.
MRI was performed in 20, 70, and 100% of controls, RTHβ,
and TSHoma, respectively.
FIGURE 2 | TRH stimulation test results. The three curves represent the mean
TSH values ± SEM at baseline, 20, 30, and 60min after TRH injection in
TSHoma and RTHβ patients and controls.
RESULTS
TRH Stimulation and T3 Suppression Tests
Both TSH peak and fold increase response to TRH were blunted
in TSHoma patients compared with RTHβ or controls (p <
0.001), whilst RTHβ cases showed a greater fold increase in
TSH compared with controls (p < 0.001; Table 1). We obtained
comparable results following exclusion of RTHβ and TSHoma
patients with high baseline TSH levels (data not shown).
The TSH response curves following TRH stimulation in
controls, RTHβ and TSHomas are summarized in Figure 2. With
the TSH fold increase to TRH being similar in men and women
with TSHoma or RTHβ (not shown), we did not identify a
gender-specific TSH cut-off.
From ROC curve analysis of TSH fold increase, we identified
a cutoff of >5.2 (92% sensitivity; 96.2% specificity) that
differentiates TSHomas from RTHβ (not shown).
TSH levels after T3 suppression were higher in TSHoma (1.9
± 1.5 mean ± SD) than in RTHβ (0.3 ± 0.5; p < 0.001) or
controls (0.02 ± 0.02; p < 0.0001), while in RTHβ were not
statistically different than in controls. ROC analysis identified
TSH cut-off values post T3 suppression of <0.11 µUI/ml (not
shown). This value allowed 100% specificity (each TSHoma had
a TSH > 0.11), with all controls being correctly identified as not
having a TSHoma.
However, after T3 administration we found overlapping TSH
values between 5 RTHβ patients and the TSHomas (Figure 3).
Other Investigations
In most cases, we performed a TRH test after T3 administration.
In controls, we found a complete suppression of TSH response.
Most RTHβ patients exhibited a partially suppressed TSH
response; however, two RTHβ cases (carrying the THRB variants
p.R429Q and p.Y321C) who showed incomplete suppression
Frontiers in Endocrinology | www.frontiersin.org 4 July 2020 | Volume 11 | Article 432
Campi et al. Differential Diagnosis of Central Hyperthyroidism
FIGURE 3 | T3 suppression test. Scatter plot of the TSH values after T3 administration for 10 days in TSHomas, genetically-proven RTHβ and controls. In the right
panel, the detail of patients with RTH with TSH values were overlapping those of TSH-oma patients.
of baseline TSH levels (0.6 and 0.5 µIU/ml, respectively),
maintained a significant TSH response to TRH (5.3 and 3.9,
respectively). In 100% of the TSHoma patients, baseline TSH
levels did not suppress after T3 but retained response to TRH in
about 15% of cases.
Thirteen TSHoma and four RTHβ patients underwent a short
course of LAR-SMS injections (30 mg/28 days for 2 months). In
TSHoma, the average reduction in FT3 and FT4 levels was 40.1
± 2 and 46.3 ± 24% (mean ± SD), while in RTHβ it was 11.7
± 4 and 7.2 ± 6%, respectively. Two TSHomas were resistant
to LAR-SMS.
Pituitary MRI showed abnormalities compatible with a
microadenoma in 11/45 RTHβ and in 3/7 patients with spurious
hyperthyroxinemia whereas a pituitary microadenoma was not
visualized initially in 6/26 TSHomas (Table 1).
Alpha glycoprotein subunit (αGSU) was measured by
radioimmunoassay in 14/26 TSHoma and 12/61 RTHβ cases,
with calculation of TSH/αGSU molar ratio. In 11/14 TSHoma
patients (79%), we found an elevated molar ratio (>1), but the
molar ratio was normal in 3/14 patients with micro-TSHoma and
increased in five postmenopausal RTHβ women.
The 66% of RTHβ patients were familial case, however in 30%
of them the thyroid function of the relatives was not performed
prior to referral.
SERIES OF CHALLENGING PATIENTS
Patient #1: (i) Referral diagnosis, assay interference; at baseline a
multinodular goiter was diagnosed and a cytological analysis of
a 20mm right sided thyroid nodule ruled out malignancy. The
patient’s earliest tests showed discrepant TFTs (TSH 3.93 µUI/ml
RR 0.28-4.8; FT4 21.6 pmol/l RR 10-20; FT3 7.6 pmol/l RR 2.9–7),
but results were dissimilar when repeated in a different laboratory
(TSH 4.1 µUI/ml RR 0.28–4.8; FT4 16 pmol/l RR 10–20 FT3 5.9
pmol/l RR 2.9–7), suggesting assay interference. Levothyroxine
(L-T4) therapy was introduced aiming to reduce the goiter
volume. Despite the lack of TSH suppression, a 50% reduction of
the nodule was seen but accompanied by a progressive rise of FT4
and FT3. Nevertheless, this was interpreted as overtreatment and
L-T4 was discontinued on July 2007. During 3-years follow-up,
FT4 and FT3 normalized. Later, the patient underwent surgery
for renal cell carcinoma and endocrine evaluation was deferred
for 2 years.
(ii) Interventions: At that time the IST became evident
and persistent, assay interference was definitely excluded by a
two-step method for TH determination. TSH levels did not
increase after TRH stimulation and MRI scan showed a pituitary
macroadenoma extending into the right suprasellar cistern
(Table 2). Increased PRL levels (110.1 ng/ml, reference range (RR
3–20) were also found. LAR-SMS was started, as the patient
refused surgery. Thyroid function and PRL levels normalized,
suggesting a TSH/PRL cosecreting macroadenoma, while the
dimension of the adenoma showed only a small change over 5-
years of follow-up (12 and 10mm in 2012 and 2017, respectively).
The reason for normalization of PRL levels is unclear (22, 23), but
this phenomenon is more likely to occur in mixed adenomas. (iii)
Ultimate diagnosis, mixed PRL/TSHoma.
Patient #2: (i) Referral diagnosis, undetermined IST; The
patient presented with multinodular goiter and IST, discovered
during investigations for a paroxysmal atrial fibrillation (PAF).
PAF was corrected by pharmacologic cardioversion and beta-
blockade. An impaired TSH response to i.v. TRH test was found
(Table 2). A pituitary MRI showed a right upward convexity
without clear evidence of adenoma after gadolinium. (ii)
Interventions: A LAR-SMS trial normalized FT3 and FT4 after
3-months, confirming the diagnosis of TSHoma (Table 2). This
therapy was well tolerated for 2 years, but then an attack of biliary
colic necessitated discontinuation of LAR-SMS and treatment
with methimazole (MMI) instead, prior to cholecystectomy. As
expected, TSH increased markedly and after 6 months of MMI,
pituitary MRI scan now visualized an 8mm right sided lesion
consistent with microadenoma. Likely, MMI had promoted
the growth of a microadenoma which was then uncovered.
The patient underwent trans-sphenoidal surgery (TSS) and
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TABLE 2 | Clinical characteristic of the 14 patients included in the case series.
Patient #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 #12 #13 #14
Age (range) 60–65 70–75 18–25 18–25 36–40 18–25 40–45 30–35 30–35 50–55 40–45 50–55 30–35 26–30
Referral diagnosis interf. IST TSHoma RTHβ interf TSHoma RTHβ TSHoma RTHβ RTHβ RTHβ TSH-oma
+ GD
thyroiditis interf
Ultimate diagnosis TSHoma TSHoma +
ATA
interf interf TSHoma +
GD
RTHβ TSHoma interf interf interf interf interf TSHoma RTHβ
diagnostic delay
(months)
36 12 24 24 60 36 24 36 24 24 12 6 15 28
TSH uUI/ml 5.65 1.2 2.1 2.77 1.290 1.3 3.1 1.25 0.81 2.8 2.43 0.57 2.75 1.58
FT4 pmol/L 24.5 25.6 48.7 23.1 23.3 35.3 41.6 34.4 23.2 36.1 22.4 62.5 17.6 26.8
FT3pmol/L 6.3 11.8 17.7 7.3 7.3 8.13 23 12.5 9.5 14.3 10.1 11.5 8.0 6.9
SHBG nmol/L 76* - 29.7** 31** 162.0* NA 166* 80* 131* NA 74* 77* –
TRH test (TSH
peak)
7.84 2.5 7.32 9.7 1.7 10.3 27.3 11.8 8.7 18.8 20.9 NA 4.55 21.5
T3 test (TSH) – – – 0.005 1.3 – 2.7 0.001 0.005 – – – 1.76 –
TSH uUI/ml LAR* 2.86 0.84 1.6 1.4 0.025 – 1.2 – – – – – – –
FT4 pmol/L LAR* 10.1 19.7 34.4 17.6 20.9 – 16.1 – – – – – – –
FT3 pmol/L LAR* 3.7 7.4 13.2 3.8 6.6 – 6.4 – – – – – – –
Thyoid NG NG NG AITD G, AITD G NG Normal Normal Normal Normal NG NG AITD
Pituitary MRI 12mm 8mm 3mm 3mm no 3mm 4mm no 7mm no no NA 2mm 3mm cyst
THRB gene wt wt wt wt wt R429Q wt wt wt wt wt NA NA M310V
Comorbidities RCC PAF DMD Lipodystrophy,
hyper-
insulinemia
GD none none HT HT HT, PAF
MGUS
HT MGUS – Bipolar
disorder
TSS (Y/N) N Y N – N Y Y – – – – – Y N
Histology – TSHoma – – – Normal
pituitary
Pituitary
adenoma
– – – – – TSHoma –
Cured – Y – – – – Y – – – – – Y –
Other therapies SMS-LAR – SMS-LAR – MMI,
SMS-LAR
– HRT – beta-blockers beta-blockers Beta-
blockers
– – Topiramate,
TCAs
interf., assay interference; HRT, hormonal replacement; NA, Not available; G, goiter; NG, nodular goiter; AITD, autoimmune thyroiditis; ATA, autonomous thyroid adenoma; SMS-LAR, long-acting-release somatostatin analog; MMI,
methimazole; RCC, Renal cell carcinoma; PAF, paroxysmal atrial fibrillation; MGUS, monoclonal gammopathy of undetermined significance; DMD, Duchenne muscular dystrophy; GD, Graves’ disease; HT, Hashimoto thyroiditis; TCA,
tricyclic antidepressant; Pt variant, pathogenic variant in the THRB gene. *56 days after SMS-LAR, Reference ranges: SHBG: **Male 10–70; *Female 50–144; TSH 0.3–5.1 mU/L; FT4 10–20 pmol/L; FT3 4.2–7.5.
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histological examination confirmed a TSHoma. Postsurgically,
TSH was persistently suppressed and unresponsive to TRH
stimulation, but with FT3 and FT4 levels remained normal.
Thyroid scintigraphy revealed a hyperfunctioning right nodule
with suppressed contralateral lobe uptake. Following subsequent
thyroidectomy and L-T4 replacement, euthyroid status was
finally achieved. (iii) Ultimate diagnosis, TSHoma associated
with autonomous thyroid nodule.
Patient #3: (i) Referral diagnosis, TSHoma. This patient
had Duchenne muscular dystrophy (DMD) of childhood onset.
Biochemical evaluation for low bone density showed discrepant
TFTs, confirmed on different assay platforms. Although TPO-
Ab and Tg-Ab were negative, thyroid ultrasonography showed
heterogeneous echotexture with pseudonodules. The TRH test
showed a normal increase of the TSH after TRH stimulation, and
MRI scan showed a 3mm left-sided pituitary lesion. Sequencing
of THRB and ALB did not identify any pathogenic variants. With
T3 administration being contraindicated due to DMD, a LAR-
SMS trial (20 mg/day) was undertaken, with normalization of
FT4 and FT3. Twelve months later FT4 became elevated again,
while FT3 levels were within the normal range. LAR-SMS dosage
was increased up to 30 mg/28 days without improvement. (ii)
Interventions: Thyroid function was rechecked using a two-step
assay platform and found to be normal (FT4 14.8 pmol/L, RR
10–20, total T4 (TT4) 118.9 nmol/l, RR 69.0–141.0 nmol/L).
Thyroxine binding globulin (TBG) levels were low (13µg/ml RR
14–31), probably due to corticosteroid treatment. In addition,
he was also taking biotin as a supportive therapy for DMD,
which might have caused interference with avidin/streptavidin-
based assay methods (24). (iii) Ultimate diagnosis, biotin
assay interference.
Patient #4: (i) Referral diagnosis, RTHβ. In this patient,
discrepant TFTs (TSH 1.67µIU/ml RR 0.28–4.3, FT3 15.8 pmol/l
RR 2.9–7; FT4 91.6 pmol/l RR 10–20), were discovered during
investigation for lipodystrophy, hyperinsulinemia, and weakness.
TSH increased 5-fold following TRH stimulation and suppressed
after T3 administration. A 3mm pituitary lesion was visualized
on MRI scan. LAR-SMS administration for 3 months resulted
in reduction of FT3 and FT4 (29% FT4; 26% FT3) levels. TPO-
Ab and Tg-Ab were both negative, and thyroid ultrasound scan
showed a slightly heterogeneous pattern. Sequencing of THRB
and ALB in the patient did not identify any pathogenic variant.
(ii) Intervention: TFTs were rechecked using a two-step assay
platform and found to be normal (FT4 13.2 pmol/l RR 10–20
and TT4 93.9 nmol/l RR 69.0–141.0). Thyroxine binding globulin
(TBG) levels were normal (20.6 nmol/L RR 14-31); (iii) Ultimate
diagnosis, assay interference, but its cause remains unclear.
Patient #5: (i) Referral diagnosis, assay interference. The
patient first presented with panic disorder, but at that time
thyroid function was normal. One year later, thyroid function
tests consistent with IST were noted but not confirmed on
a second sample and the patient was discharged with no
further investigation. Five years later, a relapse of psychiatric
symptoms was associated with recurrent discrepant TFTs.
Thyroid ultrasound scan showed a pattern suggestive of
autoimmune thyroid disease. Assay interference due to macro-
TSH was excluded by PEG precipitation of serum and column
chromatography. (ii) Interventions: TSH levels did not change
following TRH stimulation or T3 suppression. MRI scan showed
no pituitary lesion. LAR-SMS treatment for 3 months resulted
in reduction of FT4 and FT3, consistent with an underlying
TSHoma (Table 2). However, 20 days after the last LAR-SMS
injection thyrotoxic symptoms worsened, now associated with
suppressed TSH and positive TRAb level, leading to diagnosis of
Graves’ disease (GD) in combination with TSHoma. The patient
had no features of Graves’ orbitopathy. FollowingMMI treatment
FT4 and FT3 normalized, but eventually FT3 and FT4 rose again
with concurrent normal TSH levels after MMI discontinuation.
(iii) Ultimate diagnosis, TSHoma.
Patient #6: (i) Referral diagnosis, TSHoma. The patient
was diagnosed with IST and MMI treated for a few months.
After discontinuation of thionamide, the patient underwent
MRI scan, visualizing a pituitary lesion compatible with
microadenoma. Although TSH levels rose normally after TRH
stimulation (Table 2), the patient proceeded to TSS without
further investigation. Histological examination of removed
tissue showed no evidence of adenoma. Furthermore, IST was
unchanged after surgery and she was referred to us in 1997.
(ii) Interventions: We assessed thyroid function in first-degree
relatives, documenting IST in three of cases. Sequencing revealed
the heterozygous R429Q THRB mutation in all of them. (iii)
Ultimate diagnosis, RTHβ.
Patient #7: (i) Referral diagnosis, RTHβ. The patient presented
with tremor and weight loss. Thyroid function tests showed IST
with positive anti-thyroid autoantibodies. Thyroid ultrasound
showed a multinodular goiter and FNAB of a 33mm nodule
excluded malignancy. A TRH test showed a normal rise in
TSH and the pituitary MRI scan was negative. The patient was
classified as a case of non-TRβ-mediated RTH and monitored.
Over the next 2 years, baseline TSH, FT3, and FT4 levels
increased and the peak TSH response following TRH stimulation
showed a diminished increment compared to baseline (4 and
9 fold increase, respectively). (ii) Interventions: Suppression
of TSH following T3 administration was blunted (from 5.9
to 2.7 µUI/ml) but still responsive to TRH (TSH peak 19.7
µUI/ml). Treatment with LAR-SMS normalized FT4 and FT3
levels. Repeat MRI scan now showed a small pituitary lesion and
the patient underwent TSS and then developed hypopituitarism.
Histopathology confirmed the presence of a TSHoma. (iii)
Ultimate diagnosis, TSHoma.
Patient #8: (i) Referral diagnosis, TSHoma. The patient was
diagnosed with autoimmune hypothyroidism on the basis of
raised TSH (5.06 µUI/ml), normal free thyroid hormones (FT4
12 pg/ml RR 7.5–17.5, FT3 3.7 pg/ml 2.3–4.2), and positive anti-
TPO antibodies. Due to concurrent mild hyperprolactinemia
(PRL 57 ng/ml; RR 3–20), the patient underwent pituitary MRI
scan which showed a normal gland. L-T4 treatment promptly
normalized thyroid function and PRL levels. Five years later, IST
became apparent and persisted despite discontinuation of L-T4.
This biochemical picture was confirmed in different laboratories
and mild symptoms of hyperthyroidism were noted, raising
suspicion of a TSHoma. However, dynamic tests were suggestive
of RTHβ (Table 2) and a further MRI scan was negative. (ii)
Intervention: When tested using a two-step assay, patient’s
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thyroid function was found to be normal (TSH 3.03 µUI/ml,
FT4 16.1 pmol/l, FT3 7.2 pmol/l, and TT4 levels 92.9 nmol/l, RR
69–141 nmol/L). (iii) Ultimate diagnosis, assay interference.
Patient #9 (i) Referral diagnosis, RTHβ. She presented
with discrepant TFTs and this was confirmed in different
laboratories. Tg-Ab and TPO-Ab were negative and she had
a normal thyroid gland on ultrasonography. Pituitary MRI
scan showed a 7mm left-sided lesion with deviation of
the pituitary stalk. Mild osteopenia and tachycardia, treated
successfully with beta blockade, was documented. The TSH
response to TRH stimulation and T3 suppression was normal
and THRB sequencing was negative, such that the patient was
classified as “non-TRβ-RTH” with a non-functioning pituitary
incidentaloma, and monitored. (ii) Intervention: When retested
using a two-step assay platform, FT4 (13.9 pmol/L), FT3
(4.5 pmol/L), and TT4 (111 nmol/L RR 69.0–141.0 nmol/L)
levels were found to be normal. (iii) Ultimate diagnosis,
assay interference.
Patient #10 (i) Referral diagnosis, RTHβ. In this patient IST
was identified during investigation for PAF. The biochemical
pattern was confirmed in different laboratories and the TSH
response to TRH stimulation was normal while T3 suppression
test was contraindicated. MRI scan showed a normal pituitary
gland, whilst ultrasound showed a slightly hypoechoic thyroid
and 99-Tc scan thyroid uptake was normal. Anti Tg-Ab levels
were negative and anti TPO-Ab positive. (ii) Intervention: THRB
and ALB sequencing did not identify any variants. High TT4
(213.1 nmol/L RR 69.0–141.0 nmol/L) and a normal FT4 levels
by a two step-assay (10.4 pmol/L) were documented, suggesting
interference due to antibodies (5). At serum electrophoresis we
found two monoclonal IgA K-chain components (0.50 g/dL and
<0.30 g/dL, respectively) which may explain this interference
(25–27). (iii) Ultimate diagnosis, assay interference.
Patient #11: (i) referral diagnosis, RTHβ. Discrepant TFTs
were discovered during investigation for weight loss and
thyrotoxic symptoms. The discrepant pattern of TFTs was
confirmed in a second laboratory, the TSH response to
TRH stimulation was normal, but the patient declined a T3
suppression test. MRI showed a normal pituitary gland and the
thyroid gland had a normal ultrasonographic appearance. Anti
Tg-Ab and anti TPO-Ab levels were negative. (ii) Interventions:
THRB and ALB sequencing was normal. When retested using a
two-step assay platform, we found normal TT4 (108.6 nmol/L RR
69.0–141.0 nmol/L) and FT4 (12.1 pmol/l) levels. (iii) Ultimate
diagnosis, assay interference.
Patient #12: (i) referral diagnosis, TSHoma, and Graves’
disease. This patient presented with hyperhidrosis and
tachycardia and discrepant TFTs (TSH 0.57 and 0.44 µUI/ml,
FT4 62.5, and >100 pmol/l, FT3 11.5, and 12 pmol/l). The
patient had a multinodular thyroid gland on ultrasonography
along with high TRAb levels (21.6 UI/ml RR < 1.6) leading
to the suspect of a TSHoma associated with Graves’ disease.
(ii) Interventions: SHBG were inappropriately normal for
hyperthyroidism (77 pmol/l RR 50–144), the 99mTc uptake
was normal and not clear signs of thyroxicosis were found
at clinical assessment. At serum electrophoresis a significant
monoclonal IgM peak (1.36 g/dl) was found. Patient’s thyroid
function reassessed by another one-step platform (Beckman)
resulted in normal FT3 and slightly elevated FT4 levels (TSH
0.92 RR 0.34–5.6 µUI/ml; FT3 3.85 pg/ml RR 2.5-3.9; FT4 1.33
ng/dl RR 0.61–1.12) while a two-steps assay showed normal free
and total TH (FT4 12.9 pmol/l RR 10–20, TT4 94.9 nmol/L RR
69–141, TT3 1.5 nmol/L RR 1.3–2.5). Several other endocrine
and not endocrine abnormalities were found which were all
reversible after 20% PEG precipitation or serial serum dilution of
the serum. Six sandwich immunoassays (TSH, LH, FSH, ACTH,
PTH, and PRO-BNP) were underestimated, while competitive
assays (FT4, FT3, and TRAb) were overestimated, as previously
reported in patients with paraproteins (25, 27). (iii) Ultimate
diagnosis: assay interference.
Patient #13: (i) Referral diagnosis, thyroiditis. The patient
presented with slightly high FT3 levels (8 pmol/l) associated
with a normal TSH and FT4 (2.75 µUI/ml and 17.6 pmol/l,
respectively) with mild thyrotoxic symptoms. A thyroid
scintigraphy showed an area of reduced uptake in the right lobe
without US detectable nodules which was attributed to a “silent”
thyroiditis. No further investigation were performed for 1 year,
although persistent high FT3 levels. (ii) interventions: TRH
test and T3 suppression were performed and consistent with a
TSHoma (Table 2). A 3mm pituitary lesion was found by MRI.
After TSS, baseline and TFTs, normalized and TSH retained a
normal response to TRH and T3 administration in the following
10 years. Six months prior to TSS a left 4 cm thyroid cyst was
noted which was treated with percutaneous ethanol injection.
(iii) Ultimate diagnosis, TSHoma.
Patient #14: (i) Referral diagnosis: drug-induced artifact.
This patient presented with isolated high FT4 levels (TSH 1.58
µUI/ml; FT3 4.0 pg/ml RR 2–5; 22.8 pg/ml RR 8–17), and
hyperprolactinemia (53.4 and 113.5 ng/ml RR 5–20) during
treatment with tricyclic antidepressant (clomipramine),
antipsychotic agents (olanzapine and risperidone), and
topiramate for a psychiatric bipolar disorder. At MRI a
3mm cyst of the pars intermedia of the pituitary was found.
TPO-Ab and Tg-Ab were negative although a US thyroid pattern
suggestive of AITD; a normal TSH response to TRH was found.
(ii) Interventions: 2 years later, FT4 levels persisted elevated
despite topiramate withdrawal, while PRL normalized when
cabergoline was discontinued during aripiprazole treatment.
THRB sequencing showed the p.M310V variant of the gene. (iii)
Ultimate diagnosis: RTHβ.
DISCUSSION
We reviewed baseline and dynamic testing in patients suspected
with IST, and present challenging case histories from 14 patients
in whom the correct diagnosis was either missed or delayed due
to misinterpretation of clinical data.
Reflecting our conclusions and experience we propose a
revised diagnostic flowchart (Figure 4) which encompasses and
amplifies upon published guidelines (1). In particular, we have
included a detailed description of the differential diagnosis of
interferences causing artifacts in assays of TFTs. Moreover, now
we give more emphasis to T3 suppression than TRH test or
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FIGURE 4 | Flowchart for more effective differential diagnosis of inappropriate TSH secretion. This flow-chart represents our proposed cost-effective work up for the
differential diagnosis of inappropriate TSH secretion. Final diagnoses are indicated in bold; optional tests are indicated in parentheses. AD, autosomal dominant; ALB,
albumin gene; FDH, Familial dysalbuminemic hyperthyroxinemia (FDH); HAMA, Human anti-mouse antibodies; MEN1, Multiple Endocrine Neoplasia type 1; MLPA,
Multiplex Ligation Probe Amplification; MMI, methimazole; NGS, next generation sequence; PEG, polyethylene glycol; SMS-LAR, long-acting-release somatostatin
analog; TFTs, thyroid function tests; TH, thyroid hormones; TT4, total T4; TT3, total T3.
peripheral markers of TH action, and we excluded from the
investigations the αGSU because of its unavailability in routine
settings worldwide. We also provide specific cut-offs for the
interpretation of T3 suppression test. In addition, we have
indicated how the diagnosis of non-TR-RTHβ can be reached
by a combination of dynamic tests and peripheral markers of
TH action. Finally, we propose the administration of anti-thyroid
drugs in selected cases of microTSHoma under the limits of MRI
detection but diagnosed by SMS-LAR test. This would accelerate
the growth of an underlying lesion within some months and then
allow the surgical approach.
Our observations indicate assay interference as the
main source of error that is still too often underestimated.
Unfortunately, the widespread use of high-throughput platforms
based on one-step assays has increased the frequency of
assay artifact, due to interference from biotin, circulating
heterophilic antibodies or abnormal binding proteins for
example. Automated, one-step, measurement technologies are
reproducible and cost efficient, favoring their use over more
robust and bespoke two-step methods (where the labeled TH is
added only after incubation of serum with the anti-TH antibody
in solid phase and the washing step removing all potential
interfering substances), particularly when assay services are
centralized in laboratories following competitive tendering
processes. However, the lack of robust assays in referral centers
investigating difficult cases using complex investigation pathways
may paradoxically increase the costs of diagnosis. Thus, in this
patient cohort, cases of apparently discrepant TFTs due to assay
interference were investigated with pituitary imaging, dynamic
endocrine testing, genetic analyses and LAR-SMS test (Patient #3
and #4). In addition, patient 4 underwent LAR-SMS treatment
for further 15 months. According to the schedule of charges
in the National Health System in Italy, these procedures and
treatments caused an estimated cost >35,000 e (∼37,000 USD),
not taking into account the indirect costs (e.g., working hours
lost due to unnecessary investigation). Conversely, the cost of
thyroid function testing for these six patients using a two-step
assay would have been lower than 300 e.
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In addition, we recommend retesting TFTs periodically and
with different assays when the source of the assay interference is
not clearly evident. Interestingly, in three patients with genuine
TSHomas (#1 and #13) or RTHβ (#14) the presence of an isolated
high FT4/FT3 delayed the correct diagnosis being attributed to
an artifact.
Previous literature data suggest that several variables
(gender, thyroid autoimmunity, and other thyroid dysfunctions)
can influence the response to dynamic endocrine testing—
particularly the TRH stimulation test (1, 18, 28). Indeed, in
order to improve its specificity, some authors have suggested
performing the TRH test following the administration of
L-T3 for 3 days (14). Such testing would show complete
suppression of the TSH response to TRH in normal individuals,
partial suppression of TSH response in patients with RTHβ,
and no suppression in TSHoma cases. However, in our
cohort, two genetically-proven RTHβ patients showed
TSH levels between 0.5 and 0.6 even 10 days after T3
administration, raising doubts about the ability of T3
administration for a shorter period of 3 days to suppress
TSH levels effectively.
Patient #7 exhibited a 9-fold rise in TSH after TRH, possibly
due to coexisting Hashimoto’s thyroiditis; due to absence of
features of a pituitary tumor she was incorrectly diagnosed
as “non-TRβ-RTH.” Ultimately, reevaluation of thyroid status
in this patient proved to be the most correct strategy. As
previously reported (28) the diagnosis of a TSHoma can
be delayed if initial investigations are suggestive of RTHβ.
In our patient and in the two patients of Macchia et al.
(28), the administration of LAR-SMS clarified the diagnosis.
Conversely, in the differential diagnosis of discrepant TFTs,
concomitant primary hyperthyroidism can cause a blunted
response to TRH. For example, one RTHβ patient with an
underlying “warm” thyroid nodule showed a blunted TSH
response (baseline TSH 0.26; peak TSH 3.2 µUI/ml) at TRH
test. Our observations suggest that in patients with coincident
primary thyroid disease (e.g., autoimmune thyroid disease
or multinodular goiter), the T3 suppression test alone, or
in combination with response to LAR-SMS administration,
has the highest diagnostic specificity for TSHoma, with the
TRH stimulation test being potentially misleading. The T3
suppression test is usually safe and absolute contraindications
(severe cardiac disorders, atrial fibrillation, untreated sinus
tachycardia, uncorrected adrenal cortical insufficiency) are
limited. The test is usually avoided in the elderly as liothyronine
may exacerbate occult underlying cardiac problems such as
ischemic heart disease, angina pectoris, arrhythmia, or congestive
heart failure.
Another observation is the variable predictive value of
negative or positive response to dynamic testing. In other
words, a subnormal TSH response following TRH stimulation
strongly suggests a diagnosis of TSHoma, but only when
thyroid autonomy has been ruled out. Conversely, complete
suppression of TSH after T3 administration excludes TSHoma,
whilst partial or incomplete TSH suppression, implying mutant
receptor insensitivity to thyroid hormone, favors a diagnosis of
RTHβ (Figure 2).
In patient #6 an excessively stringent interpretation of
MRI scan result was the main reason for misdiagnosising
TSHoma, rather than correct identification of RTHβ. Results
of the pituitary MRI scan should always be interpreted
with caution, as pituitary incidentalomas are frequent in the
general population, and so would be expected to arise as
frequently in patients with spurious hyperthyroxinemia due to
assay interference (e.g., patients #3, #4, and #9). Conversely,
micro-TSHomas may fail to be visualized in pituitary MRIs
(e.g., patients #2, #5, and #7). In some cases with an
initial negative pituitary MRI scan (e.g., patient #2), a short
course of anti-thyroid drug treatment can not only control
hyperthyroidism, but also promote an increase in size of
an underlying microadenoma which is then visualized on
further imaging. In addition, the case history of patient #2
illustrates the fact that permanently suppressed TSH levels
following pituitary surgery, in combination with detectable
TH levels while not on thyroxine therapy, may denote the
presence of concomitant, but previously hidden autonomous
thyroid nodules.
Patient #6 illustrates the high specificity of finding abnormal
thyroid function tests in first-degree relatives; thus, in
nearly 80% of RTHβ cases, testing family members can
avoid misdiagnosis and unnecessary further investigation
(27). Surprisingly, in 30% of the RTHβ cases included in
this study the patients’ relative were not screened before
referral, although the probability of having RTHβ (incidence
1:20.000–40.000 newborns) (4) is higher than that of having
a TSHoma (prevalence <1 per 1 million inhabitants)
(2, 3).
Interestingly, in two patients (#2 and #5), persistent inhibition
of TSH secretion from normal thyrotropes following surgical
removal of the TSHoma or its inhibition with LAR-SMS has
unmasked underlying, concomitant primary hyperthyroidism.
This is a possibility that should be considered in order to avoid
misinterpreting results to indicate either central hypothyroidism
following TSS (e.g., patient #2) or unresponsiveness to LAR-SMS
(e.g., patient #5).
Due to physiological decrease in FT4 and FT3 levels in second
and third trimester, pregnancy may mask diagnosis of IST. Thus,
in one patient included in this series, failure to reassess thyroid
status after delivery, caused delay in the diagnosis.
The determination of α-GSU serum levels appears to be
of limited utility in the differential diagnosis of IST. Thus,
a high α-GSU/TSH molar ratio was documented in five
post-menopausal women with genetically-proven RTHβ,
whereas 3/14 patients with micro-TSHoma exhibited a
normal α-GSU/TSH molar ratio. Our data also suggests
that the absolute magnitude of αGSU is not sensitive enough
for differential diagnosis of IST, as levels were normal in
several patients with a micro-TSHoma. As suggested by
Socin et al. (16) TSHomas are now increasingly diagnosed as
microadenomas (<1 cm), and consequently the percentage
of patients with raised αGSU levels is lower than previously
reported (29, 30).
The 14 patients included in this series experienced a diagnostic
delay of >2 years following the estimated onset of clinical
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manifestations of thyrotoxicosis. Interestingly, this interval is
similar to that reported in Cushing’ disease (31). Finally, our case
series shows that self-reported symptoms and signs in patients
can be misleading, since some individuals with assay interference
exhibited features of apparent thyrotoxicosis.
The whole of these findings has to be seen in light of its
retrospective nature. However, given the rarity of the clinical
conditions, appropriate powered prospective study should
require several decades to enroll enough cases.
In conclusion, we have retrospectively surveyed, a large
series of discrepant TFT patients and controls, and described
14 patient case histories in detail, illustrating the main pitfalls
in making a correct diagnosis. In selected cases with apparent
“non-TRβ-RTH,” a short course of LAR-SMS administration
or the T3-suppression test represented the best tools to
correctly diagnose TSHomas with paradoxical responses to TRH
stimulation. Recognition of assay interference is a mandatory
and cost-effective first-line approach in order to avoid further
unnecessary investigation and potentially harmful therapy, as the
TSH response to TRH stimulation or T3 suppression cannot
distinguish between raised thyroid hormones due to interference
in FT4 and FT3 assays or RTHβ.
A multistep investigation protocol, with careful interpretation
of all test results including molecular genetic studies, appears
to be the best strategy for correct, early differential diagnosis of
discrepant TFTs—even in those cases in which the cause appears
initially obvious (Figure 4).
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